NCT02643901View on ClinicalTrials.gov

Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

October 10, 2016

Study Completion Date

October 10, 2016

Conditions
Chemotherapy-induced Neutropenia
Interventions
BIOLOGICAL

GW003

single SC injection

Trial Locations (1)

30020

Tianjin Hematonosis Hospital, Tianjin

All Listed Sponsors
lead

Jiangsu T-Mab Biopharma Co.,Ltd

INDUSTRY

NCT02643901 - Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects | Biotech Hunter | Biotech Hunter